Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Untimely Tissue Standards Can Stall Product Development – CBER Rep

This article was originally published in The Gray Sheet

Executive Summary

Premature standards development for tissue-engineered medical products (TEMPs) could delay their entry into the market, according to Joyce Frey-Vasconcells, acting deputy director of CBER's Office of Cellular, Tissue & Gene Therapies

You may also be interested in...

Wyeth BMP-2 Panel Review Signals “Not Approvable” Issues Are Resolved

Wyeth is reinterpreting clinical data from a 450-patient pivotal study supporting a BMP-2 premarket approval application

Tissue Product Premarket Route, Legal Framework Debated By EU Regulators

The submission of European tissue product premarket filings to a "central expert body" comprising member state representatives is one of various review options explored by the European Commission in a July consultation document

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts